2022 Corporate Calendar – Update

2022 Corporate Calendar – Update Turin, 23rd June 2022. Iveco Group N.V. (MI: IVG) announces that the meeting of the Board of Directors for the approval of Q2 results has been brought forward to 27th July 2022. The conference call for investors and financial analysts is confirmed on 28th July. This will be accompanied by a listen-only webcast and presentation available to […]

Continue Reading

Sinch receives a tier one ranking in ROCCO’s latest reports for its A2P Monetization product suite and its SMS Firewall product for MNOs, and A2P SMS products for enterprises

Sinch Ranked Tier One by ROCCO Stockholm, Sweden –  23 June 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that it has been awarded the highest ‘Tier One’ ranking in recent reports from Roaming Consulting Company (ROCCO) for its Application-to-Person (A2P) SMS Monetization suite and A2P […]

Continue Reading

STARMUS VI – Out of This World Science and Arts Festival Will See Speakers Including Chris Hadfield and Kip Thorne Celebrate 50 Years of Exploration on Mars

Festival founded by astrophysicist Dr. Garik Israelian and Dr. Brian May, astrophysicist and the legendary guitarist of Queen, will be held in Armenia and dedicated to the 50th anniversary of the first soft landing on Mars by “Mars 3” and the first orbiter “Mariner 9”. Dr Garik Israelian, astrophysicist and co-founder of STARMUS LONDON, June […]

Continue Reading

Philogen Provides Corporate Update

Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft–tissue sarcoma and glioblastoma are on track. OncoFAP shows potent activity […]

Continue Reading

Philogen Provides Corporate Update

Philogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft–tissue sarcoma and glioblastoma are on track. OncoFAP shows potent activity […]

Continue Reading